$TPST
Tempest Therapeutics, Inc. Stock $tpst

$tpst Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000162828022014231 Filed on May 13, 2022

Income Statement

Concept	2022 Q1	2021 Q1
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.052M	$1.535M
YoY Change	98.83%	-66.59%
% of Gross Profit
Research & Development	$5.109M	$3.592M
YoY Change	42.23%	-52.36%
% of Gross Profit
Depreciation & Amortization	$108.0K	$78.00K
YoY Change	38.46%	110.81%
% of Gross Profit
Operating Expenses	$5.109M	$3.592M
YoY Change	42.23%	-52.36%
Operating Profit	-$8.161M	-$5.127M
YoY Change	59.18%	-57.75%
Interest Expense	$333.0K	$231.0K
YoY Change	44.16%	42.59%
% of Operating Profit
Other Income/Expense, Net	-$330.0K	-$228.0K
YoY Change	44.74%	812.0%
Pretax Income	-$8.491M	-$5.355M
YoY Change	58.56%	-55.37%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$8.491M	-$5.355M
YoY Change	58.56%	-55.37%
Net Earnings / Revenue
Basic Earnings Per Share	-$1.18	-$10.55
Diluted Earnings Per Share	-$1.18	-$10.55
COMMON SHARES
Basic Shares Outstanding	7.167M shares	507.5K shares
Diluted Shares Outstanding	7.167M shares	507.5K shares

Balance Sheet

Concept	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$45.75M	$52.27M
YoY Change	-12.46%	-9.89%
Cash & Equivalents	$45.75M	$51.83M
Short-Term Investments		$439.0K
Other Short-Term Assets	$691.0K	$1.853M
YoY Change	-62.71%	-63.53%
Inventory
Prepaid Expenses	$643.0K
Receivables
Other Receivables
Total Short-Term Assets	$62.71M	$68.96M
YoY Change	-9.07%	6.71%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.024M	$1.113M
YoY Change	-8.0%	-61.17%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$480.0K	$111.0K
YoY Change	332.43%	-80.0%
Total Long-Term Assets	$4.243M	$4.275M
YoY Change	-0.75%	24.96%
TOTAL ASSETS
Total Short-Term Assets	$62.71M	$68.96M
Total Long-Term Assets	$4.243M	$4.275M
Total Assets	$66.95M	$73.24M
YoY Change	-8.58%	7.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$684.0K	$991.0K
YoY Change	-30.98%	-64.26%
Accrued Expenses	$3.234M	$1.589M
YoY Change	103.52%	-76.42%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due		$235.0K
YoY Change		-8.91%
Total Short-Term Liabilities	$20.82M	$20.03M
YoY Change	3.94%	78.63%
LONG-TERM LIABILITIES
Long-Term Debt	$15.13M	$15.07M
YoY Change	0.42%	13599.09%
Other Long-Term Liabilities	$1.648M	$1.482M
YoY Change	11.2%	21071.43%
Total Long-Term Liabilities	$15.13M	$15.07M
YoY Change	0.42%	12779.49%
TOTAL LIABILITIES
Total Short-Term Liabilities	$20.82M	$20.03M
Total Long-Term Liabilities	$15.13M	$15.07M
Total Liabilities	$37.60M	$37.12M
YoY Change	1.28%	176.9%
SHAREHOLDERS EQUITY
Retained Earnings	-$108.6M	-$100.1M
YoY Change	8.49%	-54.66%
Common Stock	$7.000K	$7.000K
YoY Change	0.0%	-63.16%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$29.36M	-$73.95M
YoY Change
Total Liabilities & Shareholders Equity	$66.95M	$73.24M
YoY Change	-8.58%	7.63%

Cashflow Statement

Concept	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	-$8.491M	-$5.355M
YoY Change	58.56%	-55.37%
Depreciation, Depletion And Amortization	$108.0K	$78.00K
YoY Change	38.46%	110.81%
Cash From Operating Activities	-$7.107M	-$6.310M
YoY Change	12.63%	-37.9%
INVESTING ACTIVITIES
Capital Expenditures	$3.000K	$14.00K
YoY Change	-78.57%	-46.15%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$3.000K	-$14.00K
YoY Change	-78.57%	-46.15%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$1.403M	$0.00
YoY Change		-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$1.403M	$14.94M
YoY Change	-90.61%	167.38%
NET CHANGE
Cash From Operating Activities	-$7.107M	-$6.310M
Cash From Investing Activities	-$3.000K	-$14.00K
Cash From Financing Activities	$1.403M	$14.94M
Net Change In Cash	-$5.707M	-$11.81M
YoY Change	-51.68%	154.82%
FREE CASH FLOW
Cash From Operating Activities	-$7.107M	-$6.310M
Capital Expenditures	$3.000K	$14.00K
Free Cash Flow	-$7.110M	-$6.324M
YoY Change	12.43%	-37.92%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001544227
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-35890
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	Tempest Therapeutics, Inc.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-1472564
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	7000 Shoreline Court
CY2022Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 275
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco,
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
CY2022Q1	dei	City Area Code CityAreaCode	(415)
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	798-8589
CY2022Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
CY2022Q1	dei	Trading Symbol TradingSymbol	TPST
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	10323006	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	45754000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	51829000	USD
CY2022Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	15000000	USD
CY2021Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	15000000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1956000	USD
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2134000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	62710000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	68963000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1024000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1113000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2739000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3051000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	480000	USD
CY2021Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	111000	USD
CY2022Q1	us-gaap	Assets Assets	66953000	USD
CY2021Q1	us-gaap	Assets Assets	73238000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	684000	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	991000	USD
CY2022Q1	us-gaap	Litigation Reserve Current LitigationReserveCurrent	15000000	USD
CY2021Q1	us-gaap	Litigation Reserve Current LitigationReserveCurrent	15000000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3234000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1589000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1473000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1442000	USD
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	330000	USD
CY2021Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	912000	USD
CY2022Q1	us-gaap	Interest And Dividends Payable Current InterestAndDividendsPayableCurrent	94000	USD
CY2021Q1	us-gaap	Interest And Dividends Payable Current InterestAndDividendsPayableCurrent	92000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	20815000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	20026000	USD
CY2022Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	692000	USD
CY2021Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	756000	USD
CY2022Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	15133000	USD
CY2021Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	15069000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1648000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2026000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	37596000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	37121000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7173094	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7173094	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6910324	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6910324	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	7000	USD
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	7000	USD
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	137904000	USD
CY2021Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	136173000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-108554000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-100063000	USD
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	29357000	USD
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	36117000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	66953000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	73238000	USD
CY2022Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	5109000	USD
CY2021Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	3592000	USD
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3052000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1535000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8161000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5127000	USD
CY2022Q1	us-gaap	Interest Expense InterestExpense	333000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	231000	USD
CY2022Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	3000	USD
CY2021Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	3000	USD
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-330000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-228000	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-8491000	USD
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-5355000	USD
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.18
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.18
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-10.55
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-10.55
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7167255	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7167255	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	507450	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	507450	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	36117000	USD
CY2022Q1	tpst	Stock Issuance Costs StockIssuanceCosts	44000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1403000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	328000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-8491000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	29357000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-68793000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	20000	USD
CY2021Q1	tpst	Vesting Of Early Exercised Stock Options And Restricted Stock VestingOfEarlyExercisedStockOptionsAndRestrictedStock	57000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	120000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-5355000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-73951000	USD
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-8491000	USD
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-5355000	USD
CY2022Q1	us-gaap	Depreciation Depreciation	108000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	78000	USD
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	328000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	120000	USD
CY2022Q1	tpst	Noncash Lease Expense NoncashLeaseExpense	311000	USD
CY2021Q1	tpst	Noncash Lease Expense NoncashLeaseExpense	136000	USD
CY2022Q1	tpst	Noncash Interest And Other Expense Net NoncashInterestAndOtherExpenseNet	64000	USD
CY2021Q1	tpst	Noncash Interest And Other Expense Net NoncashInterestAndOtherExpenseNet	3000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-178000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	350000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-323000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-314000	USD
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1063000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-480000	USD
CY2022Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	2000	USD
CY2021Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	92000	USD
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-347000	USD
CY2021Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-240000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7107000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6310000	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14000	USD
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1403000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2022Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	15000000	USD
CY2022Q1	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	0	USD
CY2021Q1	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	59000	USD
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1403000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14944000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-5707000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	8620000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51829000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18820000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	46122000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27440000	USD
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	268000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	108000	USD
CY2022Q1	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	16000	USD
CY2021Q1	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	0	USD
CY2022Q1	tpst	Vesting Of Early Exercise Stock Options VestingOfEarlyExerciseStockOptions	0	USD
CY2021Q1	tpst	Vesting Of Early Exercise Stock Options VestingOfEarlyExerciseStockOptions	57000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	30000000	USD
CY2021Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-15
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5365899	shares
CY2021Q2	tpst	Business Combination Exchange Ratio BusinessCombinationExchangeRatio	0.0322
CY2022Q1	tpst	Stockholders Equity Note Stock Split Exchange Ratio StockholdersEquityNoteStockSplitExchangeRatio	0.0322
CY2022Q1	tpst	Stockholders Equity Note Stock Split Exchange Ratio StockholdersEquityNoteStockSplitExchangeRatio	0.0322
CY2022Q1	us-gaap	Use Of Estimates UseOfEstimates	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to research and development accruals, recoverability of long-lived assets, right-of-use assets, lease obligations, stock-based compensation and income taxes uncertainties and valuation allowances. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates.</span>
CY2022Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	643000	USD
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	949000	USD
CY2022Q1	tpst	Prepaid Research And Development Costs Current PrepaidResearchAndDevelopmentCostsCurrent	622000	USD
CY2021Q4	tpst	Prepaid Research And Development Costs Current PrepaidResearchAndDevelopmentCostsCurrent	632000	USD
CY2022Q1	us-gaap	Other Assets Current OtherAssetsCurrent	691000	USD
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	553000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1956000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2134000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1956000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1937000	USD
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	932000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	824000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1024000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1113000	USD
CY2022Q1	us-gaap	Depreciation Depreciation	108000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	78000	USD
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2249000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	748000	USD
CY2022Q1	tpst	Accrued Clinical Trial Liability AccruedClinicalTrialLiability	985000	USD
CY2021Q4	tpst	Accrued Clinical Trial Liability AccruedClinicalTrialLiability	841000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3234000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1589000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1209000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1647000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	443000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3299000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	178000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	3121000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1473000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1648000	USD
CY2022Q1	tpst	Litigation Expense Amount Covered By Insurance LitigationExpenseAmountCoveredByInsurance	15000000	USD
CY2021Q4	us-gaap	Insurance Settlements Receivable InsuranceSettlementsReceivable	15000000	USD
CY2021Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	15000000	USD
CY2022Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	15133000	USD
CY2021Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	135936731	shares
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	114686731	shares
CY2021Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	100187000	USD
	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	99414000	USD
CY2021Q4	us-gaap	Redeemable Noncontrolling Interest Equity Preferred Carrying Amount RedeemableNoncontrollingInterestEquityPreferredCarryingAmount	86706000	USD
CY2021Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	5365899	shares
CY2021Q2	tpst	Stockholders Equity Note Stock Split Exchange Ratio StockholdersEquityNoteStockSplitExchangeRatio	0.0322
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7173094	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6910324	shares
CY2022Q1	us-gaap	Dividends Common Stock DividendsCommonStock	0	USD
CY2022Q1	us-gaap	Common Stock Voting Rights CommonStockVotingRights	one
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	1.10
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	790637	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	32.82
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	303125	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.26
CY2022Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	17202	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.49
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1076560	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	25.75
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	452165	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.35
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	62468	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	10.25
CY2021Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	4368	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.66
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	5667	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.90
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	504598	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.96
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1076560	shares
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y8M19D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	25.75
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	25.75
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1076560	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1076560	shares
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P8Y8M19D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	25.75
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	25.75
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	376806	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	376806	shares
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y10M24D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	55.41
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	55.41
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	USD
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	USD
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	328000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	120000	USD
CY2021Q1	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	USD
CY2022Q1	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	24000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-8491000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-5355000	USD
CY2022Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	7167255	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	527693	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	0	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	20243	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7167255	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7167255	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	507450	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	507450	shares
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.18
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.18
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-10.55
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-10.55
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1082596	shares
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4220628	shares

Files In Submission

Name	View Source	Status
0001628280-22-014231-index-headers.html	Edgar Link	pending
0001628280-22-014231-index.html	Edgar Link	pending
0001628280-22-014231.txt	Edgar Link	pending
0001628280-22-014231-xbrl.zip	Edgar Link	pending
exhibit3112.htm	Edgar Link	pending
exhibit3122.htm	Edgar Link	pending
exhibit3212.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tpst-20220331.htm	Edgar Link	pending
tpst-20220331.xsd	Edgar Link	pending
tpst-20220331_cal.xml	Edgar Link	unprocessable
tpst-20220331_def.xml	Edgar Link	unprocessable
tpst-20220331_htm.xml	Edgar Link	completed
tpst-20220331_lab.xml	Edgar Link	unprocessable
tpst-20220331_pre.xml	Edgar Link	unprocessable
tpstbradyemploymentagreeme.htm	Edgar Link	pending
tpstdubenskyemploymentagre.htm	Edgar Link	pending
tpst_nicmaestasemploymenta.htm	Edgar Link	pending
tpst_samwhitingemploymenta.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TPST
Tempest Therapeutics, Inc. Stock $tpst

2022 Q1 Form 10-Q Financial Statement

#000162828022014231 Filed on May 13, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPST Tempest Therapeutics, Inc. Stock $tpst

2022 Q1 Form 10-Q Financial Statement

#000162828022014231 Filed on May 13, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPST
Tempest Therapeutics, Inc. Stock $tpst